

Enzymatica AB (publ)

Styrelsens redogörelse enligt 13 kap. 6 § aktiebolagslagen *Statement by the Board of Directors in accordance with Chapter 13, Section 6 of the Swedish Companies Act*

Styrelsen i Enzymatica AB (publ), org.nr 556719-9244 ("**Bolaget**"), avger härmed följande redogörelse enligt 13 kap. 6 § aktiebolagslagen (2005:551) med anledning av förestående beslut om företrädesemission av aktier under förutsättning av extra bolagsstämmas efterföljande godkännande, vid styrelsemöte omkring den 18 juli 2024.

*The Board of Directors of Enzymatica AB (publ), Reg. No. 556719-9244 (the "**Company**"), hereby submits the following statement pursuant to Chapter 13, section 6 of the Swedish Companies Act (SFS 2005:551) regarding the forthcoming board meeting on or about 18 July 2024, to resolve on a rights issue of shares subject to the subsequent approval of the extraordinary general meeting.*

Efter det att årsredovisningen för räkenskapsåret 2023 lämnades har inga händelser av väsentlig betydelse för bolagets ställning inträffat utöver de som framgår av (i) delårsrapport för perioden 1 januari – 31 mars 2024, och (ii) det pressmeddelande som listas i Bilaga A.

Subsequent to the presentation of the annual report for the financial year 2023, no events of material significance for the company's financial position have occurred other than those that are evident from: (i) the interim report for the period 1 January – 31 March 2024, and (ii) the press release listed in Appendix A.

Lund, 17 juli 2024

Lund, 17 July, 2024

Styrelsen för Enzymatica AB (publ)
The Board of Directors of Enzymatica AB (publ)

Bengt Baron

Helene Willberg

Mats Andersson

Louise Nicolin

Guðmundur Pálmason

Moa Fransson

Enzymatica AB (publ)

Delårsrapport och pressmeddelanden *Interim rapport and press releases*

Datum / Date	Beskrivning / Description
2024-04-25	Delårsrapport januari–mars 2024 <i>Interim Report January–March 2024</i>
2024-06-13	Interimsresultat från oberoende klinisk studie av ColdZyme® visar att sjukdomstiden minskar med cirka 5 dagar <i>Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days</i>

Bengt Baron

Bengt Baron
Date: 2024-07-17 07:30 CEST
Signed with Swedish BankID
Role: Chairman
Signed via account: bengt.baron@outlook.com

Helene Willberg

Helene Willberg
Date: 2024-07-17 07:39 CEST
Signed with Swedish BankID
Role: Board member
Signed via account: helene.willberg@gmail.com

Moa Fransson

Moa Fransson
Date: 2024-07-17 07:53 CEST
Signed with Swedish BankID
Role: Board member
Signed via account: moafr634@gmail.com

Gudmundur Palmason

Gudmundur Palmason
Date: 2024-07-17 08:01 CEST
OTP by phone: +447714739955
Role: Board member
Signed via account: gudmundur.palmason@strax.com

Mats Andersson

Mats Andersson
Date: 2024-07-17 08:02 CEST
Signed with Swedish BankID
Role: Board member
Signed via account: mats.andersson@lomond.se

Louise Nicolin

Louise Nicolin
Date: 2024-07-17 14:04 CEST
Signed with Swedish BankID
Role: Board member
Signed via account: louise.nicolin@gmail.com